View Item 

Show simple item record

Histologic Alterations from Neoadjuvant Chemotherapy in High‐Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation
dc.contributor.authorLucas, David R.
dc.contributor.authorKshirsagar, Malti P.
dc.contributor.authorBiermann, J. Sybil
dc.contributor.authorHamre, Merlin R.
dc.contributor.authorThomas, Dafydd G.
dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorBaker, Laurence H.
dc.date.accessioned2017-12-15T16:46:56Z
dc.date.available2017-12-15T16:46:56Z
dc.date.issued2008-04
dc.identifier.citationLucas, David R.; Kshirsagar, Malti P.; Biermann, J. Sybil; Hamre, Merlin R.; Thomas, Dafydd G.; Schuetze, Scott M.; Baker, Laurence H. (2008). "Histologic Alterations from Neoadjuvant Chemotherapy in High‐Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation." The Oncologist 13(4): 451-458.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139918
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherSoft tissue neoplasms
dc.subject.otherDrug therapy
dc.subject.otherPathology
dc.subject.otherSarcoma
dc.subject.otherNeoadjuvant therapy
dc.titleHistologic Alterations from Neoadjuvant Chemotherapy in High‐Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumPharmacology, University of Michigan, Ann Arbor, Michigan, USA;
dc.contributor.affiliationotherDepartments of aPathology,
dc.contributor.affiliationotherOrthopedic Surgery,
dc.contributor.affiliationotherInternal Medicine, and
dc.contributor.affiliationotherDepartment of Pediatrics, Wayne State University, Detroit, Michigan, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139918/1/onco0451.pdf
dc.identifier.doi10.1634/theoncologist.2007-0220
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceFisher B, Gunduz N, Saffer EA, Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983; 43: 1488 – 1492
dc.identifier.citedreferenceAdjuvant chemotherapy for localised resectable soft‐tissue sarcoma of adults: Meta‐analysis of individual data. Sarcoma Meta‐analysis Collaboration. Lancet. 1997; 350: 1647 – 1654
dc.identifier.citedreferenceZalupski MM, Baker LH, Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematol Oncol Clin North Am. 1995; 9: 787 – 800
dc.identifier.citedreferenceRouesse JG, Friedman S, Sevin DM et al. Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer. 1987; 60: 296 – 300
dc.identifier.citedreferenceZunino JH, Johnston JO, Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone. Am J Orthop. 2000; 29: 369 – 372
dc.identifier.citedreferenceRaymond AK, Chawla SP, Carrasco CH et al. Osteosarcoma chemotherapy effect: A prognostic factor. Semin Diagn Pathol. 1987; 4: 212 – 236
dc.identifier.citedreferencePicci P, Sangiorgi L, Rougraff BT et al. Relationship of chemotherapy‐induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994; 12: 2699 – 2705
dc.identifier.citedreferencePicci P, Rougraff BT, Bacci G et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing’s sarcoma of the extremities. J Clin Oncol. 1993; 11: 1763 – 1769
dc.identifier.citedreferencePicci P, Bohling T, Bacci G et al. Chemotherapy‐induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol. 1997; 15: 1553 – 1559
dc.identifier.citedreferenceBacci G, Mercuri M, Longhi A et al. Grade of chemotherapy‐induced necrosis as a predictor of local and systemic control in 881 patients with non‐metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer. 2005; 41: 2079 – 2085
dc.identifier.citedreferenceLewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99: 112 – 128
dc.identifier.citedreferenceZalupski MM, Rankin C, Ryan JR et al. Adjuvant therapy of osteosarcoma—a phase II trial: Southwest Oncology Group study 9139. Cancer. 2004; 100: 818 – 825
dc.identifier.citedreferenceMenendez LR, Ahlmann ER, Savage K et al. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma. Clin Orthop Relat Res. 2007; 455: 219 – 224
dc.identifier.citedreferenceHenshaw RM, Priebat DA, Perry DJ et al. Survival after induction chemotherapy and surgical resection for high‐grade soft tissue sarcoma. Is radiation necessary?. Ann Surg Oncol. 2001; 8: 484 – 495
dc.identifier.citedreferenceEilber FC, Rosen G, Eckardt J et al. Treatment‐induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high‐grade extremity soft tissue sarcomas. J Clin Oncol. 2001; 19: 3203 – 3209
dc.identifier.citedreferencePezzi CM, Pollock RE, Evans HL et al. Preoperative chemotherapy for soft‐tissue sarcomas of the extremities. Ann Surg. 1990; 211: 476 – 481
dc.identifier.citedreferenceTherasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205 – 216
dc.identifier.citedreferenceWorden FP, Taylor JM, Biermann JS et al. Randomized phase II evaluation of 6 g/m 2 of ifosfamide plus doxorubicin and granulocyte colony‐stimulating factor (G‐CSF) compared with 12 g/m 2 of ifosfamide plus doxorubicin and G‐CSF in the treatment of poor‐prognosis soft tissue sarcoma. J Clin Oncol. 2005; 23: 105 – 112
dc.identifier.citedreferenceSimpson‐Herren L, Sanford AH, Holmquist JP, Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 1976; 60: 1749 – 1760
dc.identifier.citedreferencePicci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985; 56: 1515 – 1521
dc.identifier.citedreferenceHuvos AG, Rosen G, Marcove RC, Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 14 – 18
dc.identifier.citedreferenceAyala AG, Raymond AK, Jaffe N, The pathologist’s role in the diagnosis and treatment of osteosarcoma in children. Hum Pathol. 1984; 15: 258 – 266
dc.identifier.citedreferenceSchmidt RA, Conrad EU 3rd, Collins C et al. Measurement and prediction of the short‐term response of soft tissue sarcomas to chemotherapy. Cancer. 1993; 72: 2593 – 2601
dc.identifier.citedreferenceKraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high‐risk, high‐grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006; 24: 619 – 625
dc.identifier.citedreferenceJimenez RE, Zalupski MM, Frank JJ et al. Multidrug resistance phenotype in high grade soft tissue sarcoma: Correlation of P‐glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer. 1999; 86: 976 – 981
dc.identifier.citedreferenceCoffin CM, Lowichik A, Zhou H, Treatment effects in pediatric soft tissue and bone tumors: Practical considerations for the pathologist. Am J Clin Pathol. 2005; 123: 75 – 90
dc.identifier.citedreferenceCasper ES, Gaynor JJ, Harrison LB et al. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer. 1994; 73: 1644 – 1651
dc.identifier.citedreferenceSchuetze SM, Utility of positron emission tomography in sarcomas. Curr Opin Oncol. 2006; 18: 369 – 373
dc.identifier.citedreferenceBlay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16: 566 – 578
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0451.pdf
Size:
609.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.